Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
HCYT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.21
N/A
NA
vs -220.00
Q2.21
N/A
-10.00
vs -20.00
Q3.21
N/A
-5.71
vs 10
Q4.21
N/A
-23.01
vs -10.00
Q1.22
N/A
NA
vs NA
Q2.22
N/A
-2.00
vs -10.00
Q3.22
N/A
-8.04
vs -5.71
Q4.22
N/A
NA
vs -23.01
Q1.23
N/A
-5.83
vs NA
Q3.23
+100%
NA
vs -8.04
Sales Growth
YoY
Current
Estimates
Q1.21
-63%
376.2K vs 1M
Q2.21
+2210%
450.5K vs 19.5K
Q3.21
-29%
460.2K vs 649.9K
Q4.21
-30%
324.7K vs 464.5K
Q1.22
+1%
379.6K vs 376.2K
Q2.22
-84%
73.9K vs 450.5K
Q3.22
-100%
NA vs 460.2K
Q4.22
-100%
NA vs 324.7K
Q1.23
-100%
NA vs 379.6K
Q3.23
NA
NA vs NA
Return on Equity
QoQ
Q3.21
+16%
0.16
vs 0.63
Q4.21
+17%
0.17
vs 0.16
Q1.22
+94%
0.94
vs 0.17
Q2.22
+68%
0.68
vs 0.94
Q3.22
+33%
0.33
vs 0.68
Q4.22
+24%
0.24
vs 0.33
Q1.23
+32%
0.32
vs 0.24
Q3.23
+5%
0.05
vs 0.32
Institutionnal Ownership
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
PNK
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.01Â ( -0.50%)
Pre-market NaN$
0.00 (0.00%)
Relative Strenght
Volume Buzz
-59%
Earning Acce
Yes
Dist 52w H.
86%Relative Strength
HCYT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Quote Panel
Key Metrics
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How HCYT compares to sector?